$65,529.92 ownership Payment -- AstraZeneca to Dr. Amy Phillips
AstraZeneca reports $65,529.92 ownership interest to Oncologist Dr. Amy Phillips for Wegovy
This page provides a detailed analysis of a $65,529.92 ownership payment from AstraZeneca to Dr. Amy Phillips. Data is from the CMS Open Payments (Sunshine Act) database.
Payment Details
| Field | Value |
|---|---|
| Amount | $65,529.92 |
| Payment Type | ownership |
| Payment Nature | Ownership or Investment Interest |
| Pharmaceutical Company | AstraZeneca |
| Physician | Dr. Amy Phillips |
| NPI Number | 1426321507 |
| Physician Specialty | Oncology |
| Location | San Antonio, TX |
| Date of Payment | 2024-10-20 |
| Related Drug/Device | Wegovy |
| Conflict Assessment | Moderate -- Worth Noting |
AI-Powered Analysis of This Payment
The following analysis was generated by artificial intelligence to help patients understand the context, significance, and implications of this pharmaceutical payment. This analysis is not medical or legal advice.
AstraZeneca made a $65.5K ownership payment to Amy Phillips, a Oncology specialist in San Antonio, TX. The payment was associated with Wegovy. AstraZeneca reported a significant ownership interest payment of $65,529.92 to Dr. Amy Phillips, an Oncologist in San Antonio, TX. This payment is categorized as an 'Ownership or Investment Interest', indicating a financial stake rather than a direct payment for services. The payment is associated with Wegovy, a drug primarily used for weight management, which may be relevant for certain oncology patients.
Patient Guidance: What This Payment Means for You
If you are a patient of Dr. Phillips, discuss any financial relationships she may have with pharmaceutical companies and how they might influence your treatment decisions. Always discuss your treatment options with your healthcare provider and ask about alternatives.
Payment Context: Is This Amount Normal?
Ownership interests are a common form of financial relationship between physicians and pharmaceutical companies, but the amount and specific drug association warrant consideration within the context of oncology practice norms.
Regulatory Context: Sunshine Act Requirements
Payments for ownership or investment interests are reportable under the Sunshine Act, requiring disclosure of financial relationships between applicable manufacturers and physicians.
Related Topics
This payment is related to the following healthcare transparency topics:
- ownership-interest
- pharma-payment
- oncology
- astrazeneca
- wegovy
- physician-payment
Understanding ownership Payments
Ownership and investment interest payments represent dividends, returns, or other financial benefits from physician ownership stakes in pharmaceutical or medical device companies. These relationships represent the most direct form of financial interest and are subject to the strictest reporting requirements under the Sunshine Act.
Frequently Asked Questions About This Payment
What was this $65.5K payment for?
This was a ownership payment of $65.5K from AstraZeneca to Amy Phillips, categorized as "Ownership or Investment Interest". It was associated with Wegovy. The payment was reported under the Sunshine Act (CMS Open Payments).
Does Amy Phillips accept pharmaceutical money?
Yes, Amy Phillips received this $65.5K payment from AstraZeneca. Under the Sunshine Act, pharmaceutical companies must report all payments to physicians exceeding $10. You can view Amy Phillips's full payment history on the CMS Open Payments database or on this site.
Is it legal for doctors to accept pharma payments?
Yes, it is legal for physicians to receive payments from pharmaceutical companies. The Physician Payments Sunshine Act (2010) requires transparency by mandating that companies report all payments exceeding $10 to CMS. These payments include consulting fees, meals, travel, speaking fees, and research grants. The law does not prohibit payments but ensures public disclosure.
Should I be concerned about this ownership payment?
A ownership payment of $65.5K should be evaluated in context. Payment does not imply wrongdoing, but patients have the right to ask their doctor about pharmaceutical relationships.
How do I talk to my doctor about pharma relationships?
You can ask your doctor directly: "Do you receive payments from pharmaceutical companies?" and "Does this affect which medications you prescribe?" Most doctors will answer honestly. You can also verify payment data yourself through CMS Open Payments (openpaymentsdata.cms.gov). Consider asking about generic alternatives and whether the prescribed medication is the best option regardless of manufacturer relationships.
What types of pharma payments are most concerning?
Ownership interests and large consulting/speaking fees are generally considered more significant than meals or small educational grants. Research payments typically fund clinical studies and are common in academic medicine. The total volume and concentration of payments from a single company may be more telling than any individual payment. Patterns matter more than individual transactions.
Does pharma money affect what my doctor prescribes?
Research shows that even small payments can influence prescribing behavior. Studies published in JAMA Internal Medicine found that physicians who received meals costing as little as $20 were more likely to prescribe the promoted brand-name drug. However, many physician-industry interactions are legitimate professional activities. The key is transparency and awareness.
How does this compare to other doctors in Oncology?
To compare this payment against Oncology averages, check the full specialty breakdown on CMS Open Payments. Payment amounts vary widely by specialty and type. Oncology physicians may receive payments for consulting, speaking, or research that are standard for the field. Individual payments should be evaluated in the context of the doctor's full payment history.
What does this payment reveal about Amy Phillips's relationship with AstraZeneca?
The payment amount is substantial for an ownership interest. This $65.5K ownership payment is part of the transparency data reported under the Sunshine Act.
Is this payment amount typical for Oncology?
The payment date is in the future (October 20, 2024), which is unusual for reported payments.
What should patients do after learning about this payment?
If you are a patient of Dr. Phillips, discuss any financial relationships she may have with pharmaceutical companies and how they might influence your treatment decisions.
What else should I know about this ownership payment?
The drug Wegovy is primarily for weight management, raising questions about its direct relevance to oncology treatment.
Related Reports
Data from CMS Open Payments. Payment does not imply wrongdoing. Consult your healthcare provider about any concerns.